Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of... 47 KB (4,277 words) - 19:46, 30 March 2024 |
methotrexate for moderate to severe rheumatoid arthritis. The biologic agent rituximab (anti-B cell therapy) is now licensed for use in refractory rheumatoid... 15 KB (1,474 words) - 08:38, 1 May 2024 |
corticosteroids. Sometimes the chimeric anti-CD20 monoclonal antibody, rituximab, is added to this treatment regimen to form the R-CHOP regimen. R-miniCHOP... 10 KB (948 words) - 12:38, 26 March 2024 |
multicenter, open-label trial of venetoclax with rituximab (VEN+R) versus bendamustine with rituximab (B+R) in 389 participants with CLL who had received... 26 KB (2,389 words) - 05:48, 7 April 2024 |
as rituximab or cyclophosphamide and high-dose corticosteroids to control the symptoms of the disease and azathioprine, methotrexate, or rituximab to... 30 KB (3,162 words) - 05:26, 13 March 2024 |
anti-CD20 monoclonal antibody rituximab (Rituxan, Mabthera) it is called R-DHAP or DHAP-R. [R]-DHAP regimen consists of: Rituximab, a monoclonal antibody, directed... 2 KB (125 words) - 16:04, 9 November 2021 |
combined today with rituximab. This regimen is then called ICE-R or R-ICE or RICE. [R]-ICE regimen consists of:[citation needed] Rituximab - an anti-CD20 monoclonal... 3 KB (183 words) - 16:45, 9 November 2021 |
Additionally, ibrutinib down-modulates the expression of CD20 (target of rituximab/ofatumumab) by targeting the CXCR4/SDF1 axis. Together, these data are... 29 KB (2,582 words) - 04:23, 2 April 2024 |
(MCL), with or without prior rituximab-containing chemoimmunotherapy treatment, is bendamustine with mitoxantrone and rituximab. In Germany in 2012 it has... 14 KB (1,239 words) - 21:21, 2 March 2024 |
follitropin alfa, infliximab, insulin aspart, insulin glargine, pegfilgrastim, rituximab, teriparatide, and trastuzumab. A research article about "Maximizing the... 95 KB (6,479 words) - 21:14, 31 March 2024 |
Mayerhoefer ME, Lukas J, Zielinski CC, Müllauer L, Raderer M (2014). "Rituximab plus bendamustine is active in pretreated patients with extragastric marginal... 22 KB (562 words) - 06:39, 30 November 2023 |
90% to less than 20%. Immunosuppressants, such as glucocorticoids, and rituximab may also be used. Platelet transfusions are generally not recommended... 41 KB (3,902 words) - 01:19, 29 February 2024 |
It is often combined with rituximab. In this case it is called R-EPOCH or EPOCH-R.The R-EPOCH regimen consists of: Rituximab: an anti-CD20 monoclonal antibody... 6 KB (684 words) - 09:38, 30 September 2022 |
promise in this technique treating anti-MAG neuropathies.[citation needed] Rituximab is considered to be one of the most promising drugs in the treatment of... 17 KB (2,039 words) - 18:54, 12 November 2023 |
Management of ME/CFS (section Rituximab) CoQ10. A potential use for rituximab was identified by two Norwegian doctors who were treating people who had cancer with rituximab; two people also had chronic... 54 KB (6,022 words) - 10:57, 4 May 2024 |
Cancer immunotherapy (section Rituximab) destruction by the immune system. Examples of such antibodies include rituximab (targeting CD-20), trastuzumab (targeting HER-2), and cetuximab (targeting... 90 KB (9,943 words) - 14:26, 10 May 2024 |
follicular lymphoma as a second line treatment to a regimen containing rituximab. It was not tested in pregnant women. Obinutuzumab has two black box warnings:... 17 KB (1,467 words) - 09:10, 9 April 2024 |
Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds. It was approved by the US Food and Drug Administration (FDA) in... 17 KB (1,666 words) - 03:17, 20 April 2024 |
Ipilimumab Nivolumab Ofatumumab Panitumumab Pembrolizumab Ranibizumab Rituximab Trastuzumab Monoclonal antibodies used for autoimmune diseases include... 47 KB (4,794 words) - 19:52, 5 May 2024 |